Four cups of coffee a day linked to 20% reduced melanoma risk
1/21/2015
Good news for coffee drinkers; consuming four cups a day could reduce the risk of melanoma skin cancer by 20%, according to a new study.
The impact of shift work on health
1/21/2015
Many recent studies suggest that the irregular hours of shift work can have a negative impact on workers’ health. We have a look at why this could be and what can be done about it.
Coffee consumption linked with reduced melanoma risk
1/21/2015
Good news for coffee drinkers; consuming four cups a day could reduce the risk of melanoma skin cancer by 20%, according to a new study.
Vanderbilt-led study identifies potential combination therapy for melanoma
1/21/2015
Melanoma is the most lethal form of skin cancer with high mortality rates. While new drugs have been approved to treat the disease, patients nearly always develop resistance to the therapies and...
Live coverage of the immune system at work
1/21/2015
To better understand what happens during immune reactions in the body, researchers at Tübingen University have developed a new way of labeling T-cells, allowing them to track the T-cell movement...
Vanderbilt-led study identifies potential combination therapy for melanoma
1/21/2015
Melanoma is the most lethal form of skin cancer with high mortality rates. While new drugs have been approved to treat the disease, patients nearly always develop resistance to the therapies and...
Out of a library with billions of artificial antibodies, researchers have identified ten that can possibly prevent cancer tumours from growing.
Manipulating Twist1's activity either to promote regeneration or target advanced tumors
1/21/2015
These results, published in the journal Cell Reports, help to unravel seemingly contradictory observations and illuminate the complexities of transcription factor action in regeneration and tumor...
Overcoming treatment resistance in prostate cancer: Roswell Park team proposes a new strategy
1/20/2015
Researchers have discovered what may be a promising new approach for controlling aggressive, treatment-resistant forms of prostate cancer.
New data supports first-line use of Vectibix for metastatic colorectal cancer
1/20/2015
Amgen has announced new data from the Phase 2 PEAK and Phase 3 PRIME studies that support the first-line use of Vectibix (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy...